Literature DB >> 19505216

Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound.

C Klawe1, M Maschke.   

Abstract

BACKGROUND: Flupirtine is a nonopioid drug without antipyretic or antiphlogistic properties and with a favorable tolerability. It constitutes a unique class within the group of nonsteroidal analgesics and displays a peculiar pharmacodynamic profile that invites the investigation of applications beyond the pain-relieving effect.
OBJECTIVE: This review describes and evaluates the pharmacologic and clinical literature regarding flupirtine and discusses its future potential.
METHODS: A search of the primary literature and conference abstracts was conducted using the keyword 'flupirtine'. Resulting articles were compiled and analyzed for this review. RESULTS/
CONCLUSIONS: Although flupirtine has gained a firm place in the treatment of acute and chronic pain in various clinical settings since its introduction, a broader range of applications remains to be explored in clinical trials. Possible neuroprotective effects due to N-methyl-d-aspartate antagonistic properties of flupirtine might be promising in the treatment of Creutzfeld-Jakob disease, Alzheimer's disease, and multiple sclerosis. Trials in these fields are forthcoming.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505216     DOI: 10.1517/14656560902988528

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  17 in total

1.  Flupirtine is a safe alternative drug in patients with hypersensitivity to NSAIDs.

Authors:  Regina Treudler; Katja Pohle; Jan Christoph Simon
Journal:  Eur J Clin Pharmacol       Date:  2011-03-09       Impact factor: 2.953

2.  Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1.

Authors:  Werner Siegmund; Christiane Modess; Eberhard Scheuch; Karen Methling; Markus Keiser; Ali Nassif; Dieter Rosskopf; Patrick J Bednarski; Jürgen Borlak; Bernd Terhaag
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 3.  Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.

Authors:  R Kohan; I A Cismondi; A M Oller-Ramirez; N Guelbert; Tapia V Anzolini; G Alonso; S E Mole; Dodelson R de Kremer; Noher I de Halac
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

4.  Flupirtine drug-induced liver injury in a patient developing acute liver failure.

Authors:  David Noiva Perdigoto; Pedro Amaro; Manuela Ferreira; Luis Tomé
Journal:  BMJ Case Rep       Date:  2018-03-09

5.  Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy.

Authors:  Dayalan Sampath; Robert Valdez; Andrew M White; Yogendra H Raol
Journal:  Neuropharmacology       Date:  2017-06-03       Impact factor: 5.250

6.  Pathology of flupirtine-induced liver injury: a histological and clinical study of six cases.

Authors:  Florian Puls; Clemens Agne; Fritz Klein; Martin Koch; Kinan Rifai; Michael P Manns; Jürgen Borlak; Hans H Kreipe
Journal:  Virchows Arch       Date:  2011-05-18       Impact factor: 4.064

Review 7.  Duloxetine for the treatment of fibromyalgia.

Authors:  Cheryl L Wright; Scott D Mist; Rebecca L Ross; Kim D Jones
Journal:  Expert Rev Clin Immunol       Date:  2010-09       Impact factor: 4.473

8.  Flupirtine-induced liver injury--seven cases from the Berlin Case-control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database.

Authors:  Antonios Douros; Elisabeth Bronder; Frank Andersohn; Andreas Klimpel; Michael Thomae; Hans-Dieter Orzechowski; Reinhold Kreutz; Edeltraut Garbe
Journal:  Eur J Clin Pharmacol       Date:  2013-12-24       Impact factor: 2.953

Review 9.  Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Authors:  Nicola Specchio; Alessandro Ferretti; Marina Trivisano; Nicola Pietrafusa; Chiara Pepi; Costanza Calabrese; Susanna Livadiotti; Alessandra Simonetti; Paolo Rossi; Paolo Curatolo; Federico Vigevano
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

10.  Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.

Authors:  Jonathan B Rosenberg; Alvin Chen; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi
Journal:  Expert Opin Orphan Drugs       Date:  2019-11-27       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.